SpringerLink
Log in

Bisphosphonate Actions on Bone and Visceral Metastases

  • Chapter
The Biology of Skeletal Metastases

Part of the book series: Cancer Treatment and Research ((CTAR,volume 118))

Abstract

Bone abundantly stores a variety of growth factors and thus provides migrating cancer cells with fertile soil. Osteoclastic bone resorption releases these growth factors providing fertile environment, which allows colonizing cancer cells to proliferate and survive. Consequently, cancer cells produce a variety of factors that in turn influence bone metabolism. This intimate partnership between cancer cells and bone will be a driving force to develop and progress bone metastases. Accordingly, suppression of osteoclastic bone resorption should be a logic approach to inhibit bone metastases. Bisphosphonates (BPs), specific inhibitors of osteoclasts, have been widely used for the treatment of bone metastases in cancer patients. In addition, recent studies suggest the possibility that BPs can reduce visceral metastases by inhibiting cell growth and inducing apoptosis in cancer cells. In this chapter, the authors will review the recent experimental results regarding the effects of BPs on bone and visceral metastases and also show their own data obtained using animal models of breast cancer metastasis. Accumulating data suggest that there is no doubt that BPs are beneficial for the treatment of existing bone metastases, while the beneficial effects of BPs on visceral metastases are not warranted yet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (France)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 117.69
Price includes VAT (France)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 158.24
Price includes VAT (France)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 158.24
Price includes VAT (France)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Adami, S. (1997) Bisphosphonates in prostate carcinoma. Cancer, 80, 1674–1679.

    Article  PubMed  CAS  Google Scholar 

  • Bataille, R. (1996) Management of myeloma with bisphosphonates. New England Journal of Medicine, 334, 529–535.

    Article  PubMed  CAS  Google Scholar 

  • Berenson, J.R., Lichtehstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsman, D.J., Heffernan, M., Seaman, J. and Knight, R.D. (1996) Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488–493.

    Article  PubMed  CAS  Google Scholar 

  • Berenson, J.R., Hillner, B.E., Kyle, R.A., Anderson, K., Lipton, A., Yee, G.C. and Biermann, J.S. (2002) American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 20, 3719–3736.

    Article  PubMed  Google Scholar 

  • Berruti, A., Dogliotti, L., Bitossi, R., Fasolis, G., Gorzegno, G., Bellina, M, Torta, M., Porpiglia, F., Fontana, D. and Angeli, A.I. (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. Journal of Urology, 164, 1248–1253.

    Article  PubMed  CAS  Google Scholar 

  • Bloomfield, D.J. (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. Journal of Clinical Oncology, 16, 1218–1225.

    PubMed  CAS  Google Scholar 

  • Body, J.J., Bartl, R., Burckhardt, P., Delmas, P.D., Diel, I.J., Fleish, H., Kanis, J.A., Kyle, R.A., Mundy, G.R. and Paterson, A. H. G. Rubens, R. D. (1998) Current use of bisphosphonates in oncology. Journal of Clinical Oncology, 16, 3890–3899.

    PubMed  CAS  Google Scholar 

  • Boisser, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F.H., Delmas, P.D. and Clezardin, P. (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Research, 57, 3890–3894.

    Google Scholar 

  • Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F.H., Colombel, M., Delmas, P., Delaisse, J.M. and Clezardin, P. (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Research, 60, 2949–2954.

    PubMed  CAS  Google Scholar 

  • Carlin, BI. and Andriole, GL. (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer, 88, (12 Suppl), 2989–2994.

    Article  PubMed  CAS  Google Scholar 

  • Clarke, N.W., McClure, J. and George, N.J.R. (1991) Morphometric evidence for bone résorption and replacement in prostate cancer. British Journal of Urology, 68, 74–80.

    Article  PubMed  CAS  Google Scholar 

  • Coleman, R.E. and Rubens, R.D. (1987) The clinical course of bone metastases from breast cancer. British Journal of Cancer, 55, 61–66.

    Article  PubMed  CAS  Google Scholar 

  • Coleman, R.E. (1997) Skeletal Complications of malignancy. Cancer, 80, 1588–1594.

    Article  PubMed  CAS  Google Scholar 

  • Croucher, P.I., De, Hendrik. R., Perry, MJ., Hijzen, A., Shipman, C.M., Lippitt, J., Green, J., Van, Marck. E., Van, Camp. B. and Vanderkerken, K. (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. Journal of Bone and Mineral Research, 18, 482–492.

    Article  PubMed  CAS  Google Scholar 

  • Diel, I.J., Solomayer, E-F., Costa, S.D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M. and Bastert, G.. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine, 339, 357–363.

    Article  PubMed  CAS  Google Scholar 

  • Diel, I.J., Solomayer, E-F., Gollan, C, Shutz, F. and Bastert, G. (2000) Bisphosphonates in the reduction of metastases in breast cancer-Results of the extended follow-up of the first study population. Proceedings of the American Society for Clinical Oncology (ASCO) Abst # 314

    Google Scholar 

  • Fisher, J.E., Rogers, M.J., Halasy, J.M., Luckman, S.P., Hughes, D.E., Masarachia, P.J., Wesolowski, G., Rüssel, R.G.G., Rodan, G.A. and Reszka, A.A. (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 96, 133–138.

    Article  PubMed  CAS  Google Scholar 

  • Fleisch, H., Reszka, A., Rodan, G., Rogers, M. (2001) Bisphosphonates: Mechanism of action. In Principles of Bone Biology (Eds. Bilezikian JP, Raisz LG, Rodan GA), Academic Press, San Diego, pp.1361–1385.

    Google Scholar 

  • Fournier, P., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M. and Clezardin, P. (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research, 62, 6538–6544.

    PubMed  CAS  Google Scholar 

  • Fromigue, O., Lagneaux, L. and Body, J.J. (2000) Bisphosphonates induce breast cancer cell death in vitro. Journal of Bone and Mineral Research, 45, 2211–2221.

    Article  Google Scholar 

  • Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Coleman, RE. and Deliras, P.D. (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. British Journal of Cancer, 82, 858–864.

    Article  PubMed  CAS  Google Scholar 

  • Green, J.R., Muller, K. and Jaeggi, K.A. (1994) Preclinical pharmacology of CGP 42’ 446, a new, potent, heterocyclic bisphosphonate compound. Journal of Bone and Mineral Research, 9, 745–751.

    Article  PubMed  CAS  Google Scholar 

  • Hauschka, PV., Manrakos, A.E., Iafrati, M.D., Doleman, S.E. and Klagsbrun, M. (1986) Growth factors in bone matrix. Isolation of multiple types of affinity chromatography on heparin sepharose. Journal of Biological Chemistry, 261, 12665–12674.

    PubMed  CAS  Google Scholar 

  • Hillner, B.E., Ingle, J.N., Berenson, J.R., Janjan, N.A., Albain, K.S., Lipton, A., Yee, G., Biermann, J.S., Chlebowski, RT. and Pfister, D.G. (2000) American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. Journal of Clinical Oncology, 18, 1378–1391.

    PubMed  CAS  Google Scholar 

  • Hiraga, T., Williams, P.J., Mundy, G..R. and Yoneda, T. (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-231 human breast cancer cells in bone metastases. Cancer Research, 61, 4418–4424.

    PubMed  CAS  Google Scholar 

  • Hiraga, T., Ueda, A., Tamura, D., Hata, K., Williams, P.J., Ikeda, F., Yoneda, T. Effects of oral UFT combined with or without zoledronic acid on distant metastasis in the 4Tl/luc mouse breast cancer. Cancer (in press).

    Google Scholar 

  • Ho, DH., Pazdur, R., Covington, W., Brown, N., Huo, Y.Y., Lassere, Y. and Kuritani, J. (1998) Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus Nl-(2’-tetrahydrofuryl)-5-fluorouracil. Clinical Cancer Research, 4, 2085–2088.

    PubMed  CAS  Google Scholar 

  • Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J., Knight, R.D., Heffernan, M. and Reitsman, D.J. (1996a) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine, 335, 1785–1791.

    Article  PubMed  CAS  Google Scholar 

  • Hortobagyi, GN. and Piccart-Gebhart, MJ. (1996b) Current management of advanced breast cancer. Seminars in Oncology, 23 (Suppl. 11), 1–5.

    PubMed  CAS  Google Scholar 

  • Hughes, D.E., Wright, K.R., Uy, H.L., Sasaki, A., Yoneda, T., Roodman, G.D., Mundy, G.R. and Boyce, B.F.(1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research, 10, 1478–1487.

    Article  PubMed  CAS  Google Scholar 

  • Kamby, C., Andersen, J., Ejlertsen, B., Birkler, N.E., Rytter, L., Zedeler, K., Thorpe, S.M., Norgaard, T., Rose, C. (1988) Histological grade and steroid receptor content of primary breast cancer — impact on prognosis and possible modes of action. British Journal of Cancer, 58, 480–486.

    Article  PubMed  CAS  Google Scholar 

  • Koenders, P.G., Beex, L.V.A.M., Langens, R., Kloppenborg, P.W.C., Smals, A.G.H. and Benraad, T.H.J. (1991) Breast cancer study group. Breast Cancer Research and Treatment, 18, 27–32.

    Article  PubMed  CAS  Google Scholar 

  • Kostenuik, P.J., Orr, F.W., Suyama, K. and Singh, G. (1993) Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonates-treated rats. Cancer Research, 53, 5452–5457.

    PubMed  CAS  Google Scholar 

  • Lee, M.V., Fong, E.M., Singer, F.R. and Guenette, R.S. (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Research, 61, 2602–260.

    PubMed  CAS  Google Scholar 

  • Lipton, A. (1997) Bisphosphonates and breast cancer. Cancer, 80, 1668–1673.

    Article  PubMed  CAS  Google Scholar 

  • Luckman, S.P., Hughes, D.E., Coxon, F. P., Russell, R.G.G. and Rogers, M.J. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttransitional prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research, 13, 581–589.

    Article  PubMed  CAS  Google Scholar 

  • Michigami, T., Hiraga, T., Williams, P.J., Nishimura, R., Mundy, G.R. and Yoneda, T. (2002) The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Research and Treatment, 75, 249–258.

    Article  PubMed  CAS  Google Scholar 

  • Milch, R.A. and Changus, G.W. (1956) Response of bone to tumor invasion. Cancer, 9, 340–351.

    Article  PubMed  CAS  Google Scholar 

  • Mundy, G.R. and Yoneda, T. (1998) Bisphosphonates as anticancer drug. New England Journal of Medicine, 339, 357–363.

    Article  Google Scholar 

  • Paget, S. (1889) The distribution of secondary growths in cancer of the breast. Lancet, 1, 571–573.

    Article  Google Scholar 

  • Pecherstorfer, M., Ludwig, H., Zimmer-Roth, H., Schiling, T., Woitge, H.W., Schmidt, H., Baumgartner, G., Thiebaud, D., Ludwig, H. and Seibel, M.J. (1995) The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. The Journal of Clinical Endocrinology and Metabolism, 121, 542–548.

    Google Scholar 

  • Powles, T., Paterson, S., Kanis, J.A., McCloskey, E., Ashley, S., Tidy, A., Rosenqvist, K., Smith, I., Ottestad, L., Legault, S., Pajunen, M., Nevantaus, A., Männistö, E., Suovuori, A., Atula, S., Nevalainen, J. and Pylkkänen, L. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology, 20, 3219–3224.

    Article  PubMed  CAS  Google Scholar 

  • Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J.A., Apffelstaedt, J., Hussein, M., Coleman, RE., Reitsma, D.J., Seaman, J.J., Chen, B.L., Ambros, Y. (2001a) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breas cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer, 7, 377–387.

    CAS  Google Scholar 

  • Rosen, L., Gordon, D. and Tchekmedyian, S. (2001b) Zometa significantly increased the median time to first skeletal related event (SRE) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumors (OST). Lung Cancer, 34, Suppl 1.

    Google Scholar 

  • Saad, F., Gleason, DM., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A. and Chen, B. (2002) Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.

    Article  PubMed  CAS  Google Scholar 

  • Saarto, T., Blomqvist, C., Virkkunen, P. and Elomaa, I.I. (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. Journal of Clinical Oncology, 19,10–17.

    PubMed  CAS  Google Scholar 

  • Sasaki, A., Boyce, B.F., Story, B., Wright, K.R., Chapman, M., Boyce, R., Mundy, G.R. and Yoneda, T. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research, 55, 3551–3557.

    PubMed  CAS  Google Scholar 

  • Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D.D., Golub, E. and Rodan, G.A. (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation, 88, 2095–2105.

    Article  PubMed  CAS  Google Scholar 

  • Sawada, K., Morishige, K., Tahara, M., Kawagishi, R., lkebuchi, Y., Tasaka, K. and Murata, Y. (2002) Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Research, 62, 6015–6020.

    PubMed  CAS  Google Scholar 

  • Shipman, C.M., Rogers, M.J., Apperley, J.F., Russell, R.G.G. and Croucher, P.I. (1997) Bisphosphonate induces apoptosis in human myeloma cell lines: a novel anti-tumour activity. British Journal of Haematology, 98, 665–672.

    Article  PubMed  CAS  Google Scholar 

  • Shipman, C.M., Croucher, P.I., Russell, R.G.G., Helfrich, M.H. and Rogers, M.J. (1999) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Research, 58, 5294–5297.

    Google Scholar 

  • Stearns, M.E. and Wang, M. (1996) Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion and Metastasis, 16, 116–131.

    CAS  Google Scholar 

  • Takiuchi, H. and Ajani, JA. (1998) Uracil-tegafur in gastric carcinoma: A comprehensive review. Journal of Clinical Oncology, 16, 2877–2885.

    PubMed  CAS  Google Scholar 

  • Tashiro, H., Nomura, Y. and Ohsaki, A. (1994) A double blind comparative study of tegafur (FT) and UFT (a comibantion of tegafur and uracil) in advanced breast cancer. Japanese Journal of Clinical Oncology, 24, 212–217.

    PubMed  CAS  Google Scholar 

  • Theriault, R.L., Hortobagyi, G.N., Leff, R., Gluck, S., Stewart, J.F., Costello, S., Kennedy, I., Simeone, J., Seaman, J.J., Knight, R.D., Mellars, K., Heffeman, M. and Reitsman, D.J. (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Journal of Clinical Oncology, 17, 846–854.

    PubMed  CAS  Google Scholar 

  • Thomas, R.J., Guise, T.A., Yin, J.J., Elliott, J., Horwood, N.J., Martin, T.J. and Gillespie, M.T. (1999) Breast cancer cells interact with osteoblasts to support osteoclasts formation. Endocrinology, 140, 4451–4458.

    Article  PubMed  CAS  Google Scholar 

  • Urwin, G.H., Percival, R.C, Harris, S., Beneton, M.N.C., Williams, J.L. and Kanis, S.A. (1985) Generalized increase in bone resorption in carcinoma of the prostate. European Journal of Urology, 57, 721–723.

    CAS  Google Scholar 

  • Van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Lowik, C. and Papapoulos, S. (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Journal of Clinical Investigation, 98, 698–705.

    Article  PubMed  Google Scholar 

  • Yi, B., Williams, P.J., Niewolna, M., Wang, Y. and Yoneda, T. (2002) Tumor-derived PDGFBB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Research, 62, 917–923.

    PubMed  CAS  Google Scholar 

  • Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., Massague, J., Mundy, G.R. and Guise, T.A. (1999) TGFß signaling blockade inhibits PTH-rP secretion by breast cancer cells and bone metastasis development. Journal of Clinical Investigation, 103, 197–206.

    Article  PubMed  CAS  Google Scholar 

  • Yoneda, T., Michigami, T., Yi, B., Williams, P.J., Niewolna, M. and Hiraga, T. (2000) Actions of bisphosphonate on bone metastasis in animal models of breast cancer. Cancer, 88, 2979–2988.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Research, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Toshiyuki Yoneda & Nobuyuki Hashimoto

  2. Department of Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan

    Toru Hiraga

Authors
  1. Toshiyuki Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuyuki Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toru Hiraga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Michigan Comprehensive Cancer Center University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA

    Evan T. Keller DVM, PhD (Associate Professor of Urology, Comparative Medicine and Pathology) (Associate Professor of Urology, Comparative Medicine and Pathology)

  2. Emory University School of Medicine, Emory University, Atlanta, Georgia, USA

    Leland W. K. Chung PhD (Professor of Urology, Hematology/Oncology, Biochemistry and the Winship Cancer Institute) (Professor of Urology, Hematology/Oncology, Biochemistry and the Winship Cancer Institute)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Yoneda, T., Hashimoto, N., Hiraga, T. (2004). Bisphosphonate Actions on Bone and Visceral Metastases. In: Keller, E.T., Chung, L.W.K. (eds) The Biology of Skeletal Metastases. Cancer Treatment and Research, vol 118. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9129-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9129-4_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4803-0

  • Online ISBN: 978-1-4419-9129-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation